News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Thermo Fisher Scientific (TMO) and bioMerieux, Inc. Renew Partnership for Improved Detection of Sepsis Using PCT Biomarker


10/2/2012 9:54:32 AM

MARCY L'ETOILE, France & HENNIGSDORF, Germany--(BUSINESS WIRE)--bioMérieux and Thermo Fisher Scientific Inc., the world leader in serving science, today announced they have renewed their non-exclusive, long-term, royalty-bearing agreement for Procalcitonin (PCT) testing. This agreement extends a long-standing relationship between the companies for biomarker testing using Thermo Fisher’s PCT product on bioMérieux’s VIDAS® and mini VIDAS® immunoassay platforms, and now also includes the new-generation VIDAS® products.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES